Navigation Links
Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
Date:10/28/2008

studies suggest that Valortim has the potential to provide significant protection against anthrax infection when administered prophylactically post-exposure (prior to the emergence of symptoms of anthrax infection) and also may increase survival when administered therapeutically (once symptoms become evident).

About Anthrax

According to the Centers for Disease Control and Prevention, anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in hoofed mammals and can also infect humans. Symptoms of disease vary depending on how the disease is contracted, but usually occur within seven days after exposure. The serious forms of human anthrax are inhalation anthrax, cutaneous anthrax, and intestinal anthrax. Initial symptoms of inhalation anthrax infection may resemble a common cold. After several days, the symptoms may progress to severe breathing problems and shock. Inhalation anthrax is often fatal, even if treated by antibiotics. Currently, antibiotics are the only drugs available for therapeutic or prophylactic use for inhalation anthrax, and post-exposure prophylaxis is the only FDA-approved indication for such products. However, antibiotic therapy, while useful, is believed to be associated with a number of limitations, including: (1) lack of activity against the toxins produced by the B. anthracis bacteria (2) need for long-term dosing to achieve full protection, complicated by side effects and non-compliance (3) lack of efficacy when administered late in the anthrax disease cycle, and (4) lack of effectiveness against multi-drug resistant or genetically engineered strains of anthrax.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious d
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
2. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
3. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
4. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
5. Medarex to Present at the UBS Global Life Sciences Conference
6. Medarex Announces Election of Marc Rubin as New Board Member
7. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
8. Medarex Announces Completion of Sale of Shares in Genmab A/S
9. Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
10. Medarex to Present at the Susquehanna Financial Group Healthcare Conference
11. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- With over 60,000 customers across the globe, ISN improves the efficiency and effectiveness of ... than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More ... Headquartered in Dallas, TX , ISN has additional offices ...
(Date:7/30/2015)... ST. LOUIS, July 30, 2015 ... period in 2014) , Reported sales were $697 ... of 2014.  Sales grew organically by 8%, and changes ... Recent acquisitions increased sales by 1%. , By ... 8% in Applied and 11% in SAFC Commercial. ...
(Date:7/30/2015)... ... ... As part of its 2015 growth plan and as a follow up to the recently ... Whitehouse Laboratories is pleased to announce that it has begun construction on a new Microbiological ... will be strictly dedicated to basic USP 51, USP 61, and USP 62 testing specific ...
(Date:7/29/2015)... Sanofi, a global and ... quarter of 2015. CEO Olivier Brandicourt ... in different businesses. Watch video interview ... Topics covered in the interview include:  ... Performance drivers - Diabetes ...
Breaking Biology Technology:ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
... , , , ... FOLD ) will announce second quarter 2009 financial results after the ... announcement will be followed by a live conference call and webcast ... Interested participants and investors may access the conference call at ...
... , ... Change at ... constant on a constant, ... 2009 basis rates H1 2009 basis rates, ...
... , ... in Cardiac Core Lab Industry , ... Rochester, NY (PRWEB) July 29, 2009 -- iCardiac Technologies, Inc., a leader in advanced ... of 45 million cardiac cycles for agency facing studies in a single month utilizing the ...
Cached Biology Technology:Amicus Therapeutics Announces Second Quarter 2009 Financial Results Release Date 2Sanofi-aventis Announces Second Quarter 2009 Results 2Sanofi-aventis Announces Second Quarter 2009 Results 3Sanofi-aventis Announces Second Quarter 2009 Results 4Sanofi-aventis Announces Second Quarter 2009 Results 5Sanofi-aventis Announces Second Quarter 2009 Results 6Sanofi-aventis Announces Second Quarter 2009 Results 7Sanofi-aventis Announces Second Quarter 2009 Results 8Sanofi-aventis Announces Second Quarter 2009 Results 9Sanofi-aventis Announces Second Quarter 2009 Results 10Sanofi-aventis Announces Second Quarter 2009 Results 11Sanofi-aventis Announces Second Quarter 2009 Results 12Sanofi-aventis Announces Second Quarter 2009 Results 13Sanofi-aventis Announces Second Quarter 2009 Results 14Sanofi-aventis Announces Second Quarter 2009 Results 15Sanofi-aventis Announces Second Quarter 2009 Results 16Sanofi-aventis Announces Second Quarter 2009 Results 17Sanofi-aventis Announces Second Quarter 2009 Results 18Sanofi-aventis Announces Second Quarter 2009 Results 19Sanofi-aventis Announces Second Quarter 2009 Results 20Sanofi-aventis Announces Second Quarter 2009 Results 21Sanofi-aventis Announces Second Quarter 2009 Results 22Sanofi-aventis Announces Second Quarter 2009 Results 23Sanofi-aventis Announces Second Quarter 2009 Results 24Sanofi-aventis Announces Second Quarter 2009 Results 25Sanofi-aventis Announces Second Quarter 2009 Results 26Sanofi-aventis Announces Second Quarter 2009 Results 27iCardiac Processes Volume of Data Equivalent to One Thousand Traditional Thorough QT Studies 2
(Date:7/23/2015)... BEDFORD, Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... services, today reported financial results for its second quarter ended ... quarter of 2015 was $4.5 million, a decrease of 33% ...  Net income in the second quarter of 2015 was $0.3 ... million, or $0.04 per diluted share, in the same period ...
(Date:7/21/2015)... , July 21, 2015 Passwords ... as seen in the recent U.S. Office of ... solution to the infosec conundrum, but developers and ... stored. To address this dilemma, Biometrics-as-a-Service provider HYPR ... Biometric Tokenization SDK for third party integration. ...
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, 2015 /PRNewswire/ ... human interface solutions, announced today that it will report ... 2015 on Thursday, July 30, 2015 after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... Apricots are important to Turkey, the country where more ... the world. Looking to unlock the mystery of apricots, ... genetic relationship between apricot varieties. New research from a ... genetic link between Turkish and Hungarian apricot cultivars, yielding ...
... a recent issue of HortTechnology , Purdue University researchers ... study of the effects of a technique called "bulb dipping" ... applied as sprays or media drenches, bulb crops can be ... were designed to determine if dipping Easter lily bulbs in ...
... the XXI century. Recent data point to more than a ... 300 million are clinically obese. What is more, the rates ... 155 million children and adolescents being overweight, of which 40 ... what point corporal morphology was influenced by genetics, on the ...
Cached Biology News:Genetic relationship between Hungarian and Turkish apricots confirmed 2Bulb dipping controls Easter lily growth 2The amount of adipose tissue should be taken into account in the fight against obesity 2The amount of adipose tissue should be taken into account in the fight against obesity 3
... 96 wells. ELISA.Specific for total MMP-3: Recognizes ... cross-reactivity with MMP-1, -2, -9. Range: 3.75-120 ... cell culture supernatant, serum, plasma and tissue ... C. Category: Drug Screening & Cellular ...
... P Set from different human fetal ... organs maybe available upon request. ... from the whole set, and pay ... All Dr. P Set products ...
Homo sapiens inhibin, beta B (activin AB beta polypeptide) Antigen: Recombinant Protein(142~254aa)...
Self Closing Forceps...
Biology Products: